|
|
|
|
|
|
DNA Vaccines: Rapid Development and Rapid Deployment
Providing vaccines in a pandemic timeframe
|
NTC PRODUCTS AND SERVICES
|
|
|
|
NTC's new (2010), rapidly deployable set of DNA vaccination tools can be readily adapted to any antigens in a two-week, "precision cloning" turnaround service.
|
NTC's leading vector system offers the following improvments in DNA backbone architecture:
|
|
1.
|
Reduced genome (only essential sequences: increases potency, decreases recombination potential) |
|
2.
|
Trafficking (DNA to the nucleus, protein to selected presentation pathways) |
|
3.
|
Optimized expression via transcriptional and translational enhancement and a synthetic intron |
|
4.
|
Antibiotic free (meets regulatory demands) |
|
5.
|
Selected co-stimulators (activates antigen presentation, prevents tolerization) |
|
6.
|
Highest yield in the fermentor (increases purity, cost effectiveness) |
|
|
XXNTC Vector Advantages
|
|
• DNA Vaccination
• Therapeutic Vector
• Native Expression
• Secreted (TPA tag)
• Minimal Backbone
• Reporter (EGFP)
• Regulatory Compliance
• Simultaneous Cloning
Plus, choose from the following special advantages included on the Vector Selection Flowchart below.
|
A typical advanced NTC vector, NTC8685-EGFP, with the following features: markerless (sucrose selection), enhanced transcription (SV40/CMV), enhanced translation (CMV/HTLV-1-R), enhanced translation (VA1), enhanced plasmid production (PAS-BH). |
|
|
| XXVector Selection Flowchart |
*Save 20% off large scale production cost with NTC’s high-yield, SV40-PAS-BH vectors!
(for a limited time)
|
| XXCompare NTC's vectors with our competitors |
Figure 1: EGFP transgene expression (fluorescence) in human HEK293 cell line after transfection of dcm+ or
dcm- NTC8685, gWIZ and pVAX1 CMV promoter plasmid vectors.
Figure 2: NTC8385-VA1 expression compared to gWIZ-EGFP and pVAX1-EGFP in HEK293 cells.
|
| XXDNA Vaccine References |
Protection against anthrax and plague (NMRC/Porton Down/NTC), John Palmer et al., Abstract Biodefense Nov 07 31 07 (2) (3).
pDNAVACCUltra rabies DNA vaccine targeting.pdf, Kaur et al.
GPI anchored anthrax vaccine.pdf, Midha and Bhatnagar
Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune.pdf, Midha and Bhatnagar
NTC eRNA DNA Vaccines. Coexpressed RIG-I agonist enhances antigen-specific immune response to Influenza DNA Vaccine, James Williams Ph.D., Jeremy Luke, B.A., and Clague Hodgson Ph.D.
pDNAVACCUltra Vector family: high throughput intracellular targeting, 2006. James Williams, Jeremy Luke, Lance Johnson and Clague Hodgson
|
|
Contact NTC, Toll free: 1-(888) WIZ-BANG
|
|
|
